Search DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 191 - 200 of 318

Investigator:Benoit Lehallier

Title:Large-scale screening of preclinical biomarkers of Alzheimer�s disease

Date of Request:03/23/2017

Status:Pending

ID:DIAN-D1711

Aim 1:To develop new algorithms to identify reliable biomarkers of Alzheimer's disease (AD)

Aim 2:To accurately predict time to MCI or to AD

Aim 3:To investigate the relative interest of imaging, proteomics, clinical and demographics

Aim 4to validate the best models in independent data sets such as the NACC and the ADNI cohorts.

Investigator:Thomas Liebmann

Title:Validation of quantitative virtual microscopy as a novel tool for early detection of neurodegeneration and Alzheimer’s disease from magnetic resonance imaging data

Date of Request:5/4/2017

ID:DIAN-D1717

Aim 1:Establish diagnosis accuracy on confirmed Alzheimer’s disease patient MRI scans using quantitative virtual microscopy

Aim 2:Establish early detection accuracy for discriminating pre-symptomatic degeneration from non-degenerating healthy individuals using quantitative virtual microscopy analysis on MRI scans

Investigator:Paul Delmar

Title:Understand Disease Progression and iAD patient population characteristics

Date of Request:05/30/2017

Status:Approved

ID:DIAN-D1714

Aim 1:Better Understand the Disease Progression DIAD population

Aim 2:Better understand the DIAD patient population characteristics

Aim 3:Better Understand the Disease Progression proposed as primary analysis of the DIAN-TU clinical trial

Aim 4I am the Roche statistician involved with DIAN-TU clinical trial (Gantenerumab)

Investigator:Mindi Messmer

Title:Amyloid variabilty

Date of Request:07/20/2017

Status:Pending

ID:DIAN-D1721

Aim 1:Look at longitudinal amyloid in ADAD

Investigator:Eric McDade

Title:Baseline beta-amyloid and longitudinal non-amyloid biomarker changes

Date of Request:02/02/2017

Status:Approved

ID:DIAN-D1705

Aim 1:To explore the relantionship of baseline measures of amyloid pathology and subsequent change in non-amyloid biomarkers.

Investigator:Dr. David B. Pushkin

Title:Theoretical Framework Characterizing Onset of Neurodegenerative Conditions

Date of Request:03/08/2017

Status:Not Approved

ID:DIAN-D1708

Aim 1:To generate a mathematical model explaining onset and progression of PD, CTE and other related neurological conditions as a consequence of CNS trauma

Aim 2:Generate a tentative mathematical rubric for analyzing individual CSF protein biomarker concentrations with existing data pool from ongoing and published research studies

Aim 3:Generate a more comprehensive explaination regarding onset and progression of neurodegenerative conditions merging principles of neuroscience, neuropathology, statistical thermodynamics, kinetics and equilibrium

Aim 4Extrapolate pooled and individual data towards determination of potential onset dates for neurodegenerative conditions and correlation with documented CNS trauma events

Investigator:Dr. Pieter Jelle Visser

Title:AD pathology and demographic, lifestyle, and comorbid factors: a subject level meta-analysis

Date of Request:03/09/2017

Status:Approved

ID:DIAN-D1707

Aim 1:To develop an amyloid positivity screening score in subjects with normal cognition, subjective cognitive decline (SCD), mild cognitive impairment (MCI) and dementia. The screening score will be based on demographic variables, lifestyle, and comorbidity.

Aim 2:To evaluate the relation between biomarkers of amyloid positivity and other AD biomarkers in participants with normal cognition, SCD, MCI and dementia

Aim 3:To assess the impact of amyloid positivity on the course of cognitive decline in participants with normal cognition, SCD, MCI and dementia, and investigate how this is affected by demographic, lifestyle and comorbid variables.

Investigator:Berislav Zlokovic, Arthur Toga

Title:Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer�s Disease

Date of Request:03/14/2017

Status:Approved

ID:DIAN-D1709

Aim 1:To show that loss of blood-brain barrier (BBB) integrity links vascular injury to neuronal injury in AD, and provide data implicating specific brain regions in the association between BBB damage and cognitive decline as influenced by APOE4 and PSEN1 mutations

Aim 2:Examine temporal relationship between BBB permeability, cerebral blood flow (CBF) and white matter lesions (WML).

Investigator:Thomas Liebmann

Title:Validation of quantitative virtual microscopy as a novel tool for early detection of neurodegeneration and Alzheimer�s disease from magnetic resonance imaging data

Date of Request:5/4/2017

ID:DIAN-D1712

Aim 1:Establish diagnosis accuracy on confirmed Alzheimer�s disease patient MRI scans using quantitative virtual microscopy

Aim 2:Establish early detection accuracy for discriminating pre-symptomatic degeneration from non-degenerating healthy individuals using quantitative virtual microscopy analysis on MRI scans

Investigator:NA

Title:DIAN Observational Study Exploration

Date of Request:5/15/2017

ID:DIAN-D1713

Aim 1:To carry out longitudinal analysis to understand the disease progression in subjects at different phases (prodromal, mild or moderate AD)

Aim 2:To explore the relationship between EYO and onset of disease

Aim 3:To explore the relationship between biomakers (PET, CSF etc) and disease progression

Aim 4To study the impact of amyloid status and APO-E on onset of disease